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Although diagnostic tests for paediatric tuberculosis (TB) are available, no specific test has 
been tailored to fit the diagnostic challenges children present as well as cater to limited 
resource settings. The high mortality rates recorded annually are associated with late 
diagnosis as well as insufficient household contact management (HCM). Further, urine has 
been identified as an attractive biofluid for urine protein biomarker discovery. Urine is non-
invasive, easily attainable in large quantities and is associated with a low cost of collection. 
Improved data analysis approaches for protein and peptide identification and quantification 
has paved the way for the development of novel urine protein biomarkers for paediatric TB. 
Data-dependent acquisition (DDA) is a powerful approach in discovery of possible urine 
protein markers. By leveraging the shotgun proteome capabilities of protein and peptide 
identification using database search algorithms, an optimized data-independent acquisition 
(DIA) analysis method was developed. In this study, prior to data analysis, the quality of the 
DDA and DIA approach was evaluated by identifying batch effects and assessing the 
dissimilarity to allow abnormal runs to be identified and subsequently excluded. It is 
hypothesized that the quantity of specific host proteins in urine is different for children with TB 
compared to symptomatic control children who do not have TB. Using an optimised DIA data 
analysis method leveraging DDA data will allow a statistical identification of differentially 
abundant proteins in comparative proteomics. 
In this study, the MSstats R-package for protein-level abundance testing was employed to 
generate comparisons between two groups, TB cases and controls, for a South African 
human-immunodeficiency virus (HIV) negative cohort. Three human proteins, leucine-rich 
alpha-2-glycoprotein (A2GL), aggrecan core protein (PGCA) and cartilage intermediate layer 
protein 2 (CILP2) were identified as significantly different. The findings of this study support 
the hypothesis that using an optimised DIA data analysis method leveraging DDA data will 
identify the differential proteins, potentially leading to validation for use as discovery phase 




Alhoewel diagnostiese toetse vir pediatriese tuberkulose (TB) beskikbaar is, is geen spesifieke 
toets aangepas om te pas by die diagnostiese uitdagings wat kinders bied nie asook om te 
voorsien na beperkte hulpbroninstellings. Die hoë sterftesyfers wat jaarliks aangeteken word, 
hou verband met laat diagnose sowel as onvoldoende huishoudelike kontakbestuur (HCM). 
Verder is urine geïdentifiseer as 'n aantreklike biovloeistof vir die ontdekking van proteïen bio-
merkers. Urine kolleksie is nie-indringend nie, dis maklik bereikbaar in groot hoeveelhede en 
hou verband met lae versamelingskoste. Verbeterde benaderings vir data-analise vir die 
identifisering en kwantifisering van proteïene en peptiede, het die weg gebaan vir die 
ontwikkeling van nuwe urienproteïen-biomerkers vir TB in kinders. 
Data-afhanklike verkryging (DDA) is 'n kragtige benadering om moontlike 
urienproteïenmerkers te ontdek. Deur gebruik te maak van shotgun-proteoom se vermoëns 
om proteïen- en peptiedidentifikasie met behulp van databasis-soekalgoritmes te maak, is 'n 
geoptimaliseerde data-onafhanklike verkrygingsontledingsmetode (DIA) ontwikkel. In hierdie 
studie, voordat data-analise uitgevoer was, is die kwaliteit van die DDA- en DIA-benadering 
geëvalueer deur bondel-effekte te identifiseer en die verskille te beoordeel sodat abnormale 
monsters (uitskieters) geïdentifiseer en daarna uitgesluit kan word. Daar word veronderstel 
dat die hoeveelheid spesifieke proteïene in urine verskil vir kinders met TB in vergelyking met 
simptomatiese kontrole kinders wat nie TB het nie. Deur gebruik te maak van 'n 
geoptimaliseerde DIA-data-ontledingsmetode, wat gebruik maak van DDA-data, kan 
statistiese identifikasie van proteïene wat in verskillende mate in vergelykende proteomika 
bestaan, identifiseer word. 
In hierdie studie is die MSstats R-pakket vir proteïenvlak-oorvloedtoetse gebruik om 
vergelykings tussen twee groepe, TB-gevalle en kontroles, te genereer vir 'n Suid-Afrikaanse 
mens-immuungebrekvirus (MIV) negatiewe groep. Drie menslike proteïene, leucienryke alfa-
2-glikoproteïen (A2GL), aggrecan-kernproteïen (PGCA) en kraakbeen-tussenlaagproteïen 2
(CILP2) is geïdentifiseer as beduidend verskillend. Die bevindinge van hierdie studie 
ondersteun die hipotese dat die gebruik van 'n geoptimaliseerde DIA-data-ontledingsmetode 
wat gebruik maak van DDA-data, die differensiële proteïene sal identifiseer, wat moontlik kan 
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The introductory chapter sets the tone for the rest of the thesis and highlights the need for a 
biomarker-based diagnostic test against paediatric Tuberculosis. Chapter 1 also states the 
problem, contains the hypotheses as well as the aims and objectives on how we intend to 
achieve our goal.  
 
 
1.1. Background  
 
Tuberculosis (TB), one of the oldest recorded human afflictions, remains the leading cause 
of death due to infectious disease. New diagnostic strategies are needed to provide early 
detection and treatment for this epidemic that globally kills two million people per year 
(MacLean et al., 2020). Approximately 20% of annual TB case notification are children. 
Historically, child health has not been prioritised, mainly to due to perception that children 
are rarely infectious and do not develop severe active TB disease (Seddon and Shingadia, 
2014). Besides the effects of under-reporting, children are unable to produce sputum on 
demand, resulting in smear-negative paediatric TB cases. Although it would be ideal to 
confirm TB cases using culturing, these facilities are often unavailable (Graham et al., 2012).  
 
About a decade ago, researchers began to use biological samples other than sputum such 
as urine, blood, and exhaled breath for TB diagnosis. Urine became an attractive biofluid for 
use in children due to availability, accessibility, processing and storage and the low risk to 
health workers during sample collection (Peter et al., 2010). Excreted urine contains urinary 
proteins and peptides representing different stages of disease (Thongboonkerd, 2004). 
Therefore, the mechanisms of disease development and novel therapeutic targets could be 
discovered by urine proteomic approaches (Kalantari et al., 2015a; Caterino et al., 2018; 
Duangkumpha et al., 2019). Mass spectrometry (MS)-based proteomics offers a highly 
parallel multiplexed platform that enables the quantification of large numbers of proteins and 
peptides (Lin et al., 2018; Ding et al., 2020). 
 
In terms of MS-based proteomics analysis, data-dependent acquisition (DDA) remains the 
most accepted MS method for untargeted screening in discovery proteomics. With DDA 
methods, the most abundant ionized species from each precursor ion scan are selected for 





short, shotgun proteomics requires the identification of as many peptides as possible from 
complex protein mixtures (Michalski, Cox and Mann, 2011). The semi-stochastic nature of 
precursor ion selection and non-uniformity of scans, however, yield low peptide-level 
reproducibility, compromising the accuracy of the quantitative results (Kalli et al., 2014). To 
circumvent the serial nature of DDA and increase the dynamic range, a multiplexed and 
data-independent acquisition (DIA) approach was developed. Multiplexed-data acquisition is 
based on more efficient parallel co-selection and co-dissociation of multiple precursor ions, 
the data from which contain chromatograms not only for individual peptides but also for their 
fragment ions.  
 
Overall, the goals of DDA and DIA are similar; however, DIA does not select ions based on 
prior precursor ion scans. In DIA either all ions entering the MS get fragmented at every 
single point in chromatographic time or the mass-to-charge (m/z) range gets divided into 
smaller m/z ranges for fragmentation. This approach promises to improve the overall 
confidence of peptide identifications and relative protein quantification measurements 
(Chapman, Goodlett and Masselon, 2014). A comparison between conventional MS and 
multiplexed-data acquisition are shown in Figure 1.1. One such approach developed by AB 
SCIEX and the Aebersold laboratory is called SWATH-MS (MSALL), in which multiplexed 
tandem mass spectra are collected over predefined precursor ion windows termed swaths. 
The resulting signals are interpreted using prior knowledge from experimental fragmentation 
spectra (Gillet et al., 2012). DDA and DIA techniques play complementary roles, yielding 
high-throughput, quantitative consistent, and traceable data that are suitable for proteomic 






Figure 1.1. Multiplexed versus conventional MS/MS. While fragment selection and 
acquisition are sequential for the conventional mode, the multiplexed mode allows the 
acquisition of composite MS/MS spectra from multiple precursors at once. In the latter, the 
optional selection process can target contiguous or distant m/z ranges (Chapman, Goodlett 
and Masselon, 2014). 
 
1.2. Problem statement  
 
Children with tuberculosis (TB) have historically been neglected by clinicians, policy makers, 
academics, and advocates. This has largely been due to the perception that children are 
rarely infectious, and consequently contribute little to the spread of the epidemic, but also 
because of the perception that they rarely develop severe disease and because in many 
countries, children rarely have sputum smear-positive TB.  However, children with TB are 
important. Not only is there a clinical imperative to identify, diagnose, and treat children for a 
disease that is curable, but by ignoring childhood TB, efforts at epidemic TB control will 
ultimately fail. This is because children could become the reservoir out of which future cases 
will develop. The lack of a sensitive and specific test for TB in children that can be performed 
in resource-limited settings, i.e. at low cost and with little or no laboratory infrastructure, is a 
major gap in our ability to diagnose and treat children. Excreted urine contains urinary 





approaches feature high-throughput, quantitative consistency, and traceable data that are 
very suitable for urine proteomic biomarker discovery studies. 
1.3. Hypotheses  
 
It is hypothesized that the quantity of specific host proteins in urine is different for children 
with TB compared to symptomatic control children who do not have TB. Using an optimised 
DIA data analysis method leveraging DDA data will identify the abundantly differentially 
expressed proteins. 
 
1.4. Aims and Objectives  
 
Aim 1: To evaluate the quality metrics of DDA and DIA data and identify the outliers. 
 
Quality metrics for DDA data will be generated using QuaMeter IDFree (Ma et al., 2012). 
The SwaMe software (https://github.com/PaulBrack/Yamato) will be used to generate sets of 
quality metrics for the DIA data. The effect of the batches will be visualized using PCA, 
thereafter individual metrics causing variance will be identified. The outliers will be assessed 
using a dissimilarity approach. 
 
Aim 2: To analyze the DIA data leveraging from prior knowledge from DDA. 
 
The DIA data will be analyzed using Skyline software (MacLean et al., 2010). The DIA 
workflow will first be optimized using prior knowledge from DDA data. The DDA data set will 
be subjected to database searching using the MS-GF+ search engine (Kim and Pevzner, 
2014) against an Ensembl database and the MSFragger search engine (Kong et al., 2017) 
against an UniProt Knowledgebase. The protein assembly will be handled by IDPicker (Ma 
et al., 2009). To calibrate peptide retention time variation among DIA experiments, calibrant 
peptides will be selected from the two most abundant proteins commonly found in urine. For 
this, in-house spectral libraries will be made using the BiblioSpec software (Frewen and 
MacCoss, 2007) built into Skyline. The method will make use of a selected list of target 
peptides based on spectral counting. For the targeted DIA data analysis in Skyline, a 






Aim 3: To identify potential urine protein biomarkers for paediatric TB diagnosis.  
 
The cohort will be analyzed to identify the effect of age on the incidence of TB. The resulting 
Skyline document will be converted to MSstats (Choi et al., 2014) format using R. Protein-
level testing for differential abundance will be performed using the MSstats R-package. 
Comparison tests between cases and controls will be done using MSstats to identify 
significant proteins. 
 
1.5. Potential impact of the study  
 
The goal of this study is to identify urine protein biomarkers for TB in children that could lead 
to the development of simpler and more accurate tests (such as ELISA) to diagnose TB in 
children. Improved diagnosis will lead to more appropriate treatment and better outcomes for 
children with TB. To achieve this goal DIA data were optimised for identification by 
leveraging prior knowledge from DDA data.  
 
1.6. Thesis overview  
 
Chapter 2: Literature review  
This Chapter represents a literature review which provides an overview of paediatric 
tuberculosis (TB). Furthermore, it addresses the shortcomings in research on early diagnosis 
for paediatric TB. The review highlights current knowledge of shotgun discovery proteomics 
and data-independent acquisition mass spectrometry as an approach to urine protein 
biomarker discovery. 
Chapter 3: Evaluation of Quality Metrics for Data-Dependent Acquisition (DDA) 
discovery proteomics data and Data-Independent Acquisition (DIA) data acquired on a 
Q-Exactive (Thermo) instrument  
Chapter 3 evaluates the quality metrics of DDA data, and comparative DIA data acquired on 
the same instrument in the same laboratory. In this study, QuaMeter “ID-Free” software and 
SwaMe software were employed to generate quality metrics for DDA and DIA human urine 





variability through factor analysis. The variability can impact the reproducibility of an 
experiment and mask the true biological conclusion within a batch effect, thereby 
undermining the search for paediatric tuberculosis diagnostic markers.  
Chapter 4: An Optimized Data-Independent Acquisition (DIA) analysis method 
leveraging from Shotgun Proteomics Using Open-source software 
 
Chapter 4 describes the use of a data independent acquisition (DIA) workflow on a Q-
Exactive mass spectrometer for the detection and quantification of peptides using the 
Skyline Targeted Proteomics Environment. In this study, a targeted DIA data analysis 
method was optimized leveraging a comparative data dependent acquisition (DDA) data set. 
The DDA data set was subjected to database searching using the MS-GF+ and MSFragger 
search engines, respectively. The protein assembly was handled by the IDPicker algorithm. 
To allow for stable and accurate prediction of peptide retention times, the data analysis 
method employed a retention time database generated using standards representing the 
most abundant peptides commonly found in human urine proteomes. Experiment-based 
spectral libraries were created to support peptide standards selection, however, the targeted 
DIA data analysis method relied on a comprehensive human urine spectral library. 
Chapter 5: Urine Proteome for the Identification of Biomarkers for Paediatric 
Tuberculosis  
This Chapter evaluates the presence of urine protein biomarkers associated with paediatric 
TB. Data-independent acquisition (DIA) mass spectrometry was done by the Steen 
Laboratory as part of The Urine Proteomics Study conducted by Boston Children’s Hospital. 
In contrast to the initial analysis in Steen Lab employing Spectronaut software, for this study 
the protein-level quantification and testing for differential abundance were performed on a 
Skyline document using the R-package, MSstats based on a linear mixed-effects model. 
These comparison tests identify the proteins with significantly different means in the data set 
by estimating fold changes and p values that have been adjusted to control the false 
discovery rate (FDR) at 0.05.  
Chapter 6: Conclusion  
In the final Chapter all the results are taken together and the significance of what was 
discovered is discussed, shortcomings highlighted, and prospects mentioned. Altogether, the 
results point to the potential of combining DDA and DIA for novel urine protein biomarker 














This Chapter represents a literature review which provides an overview of paediatric 
tuberculosis (TB). Furthermore, it addresses the shortcomings in research on early diagnosis 
for paediatric TB. The review highlights current knowledge of shotgun discovery proteomics 
and data-independent acquisition mass spectrometry as an approach to urine protein 
biomarker discovery. 
 
2.1.  Abstract 
 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a deadly infectious 
disease for people of all age groups; however, paediatric TB is often neglected due to the 
difficulty in diagnosis. The diagnostic challenges have led to limited research conducted in 
this field. Urine collection is non-invasive and easily attainable in large quantities. Therefore, 
urine is a clinically relevant biofluid for urine protein biomarker discovery for paediatric TB 
diagnosis. In this review the diagnostic challenges and current diagnostic tests for paediatric 
TB are highlighted. The urine proteome is then described as an ideal source for protein 
biomarker discovery. The two most common approaches used in proteomics, data-
dependent acquisition (DDA) and data-independent acquisition (DIA), are then introduced. 
There is a clear need to intensify research efforts in this field, and novel urine protein 
biomarker that could be discovered DDA and DIA holds promise for paediatric TB diagnosis. 
Keywords. data-dependent acquisition; data-independent acquisition; Mycobacterium 
tuberculosis; proteomics; urine protein biomarker 
2.2.  Introduction 
 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains the most common cause 
of infection-related death worldwide. In 1993, the World Health Organization (WHO) 
declared TB to be a global public health emergency (Girardi and Ippolito, 2016). In 2017, 
about 10 million people became ill with TB and there were 1.6 million deaths caused this 
disease (WHO, 2017). People of all age groups are affected by TB with varying burden. The 
highest number of infections occurs in adults, whereas 11% of the total worldwide cases are 





placed paediatric TB lower on the priority list in the end TB strategy at global and national 
levels (World Health Organization Executive Board, 2015). The need for children specific 
diagnostics was discussed in a meeting held in 2013 that outline key actions in the roadmap 
for addressing paediatric TB (World Health Organization (WHO), 2013). 
There is a need to strengthen the evidence base that supports the need for early diagnosis 
in paediatric TB (World Health Organization (WHO), 2013). The lateral flow urine 
lipoarabinomannan (LF-LAM) assay Alere Determine™ TB LAM Ag detects a constituent of 
the cell wall of Mycobacterium tuberculosis in urine. LF-LAM is recommended by WHO to 
help detect active tuberculosis in HIV-positive people with severe HIV disease (World Health 
Organization (WHO), 2019). This biomarker-based assay has poor sensitivity and is deemed 
unreliable in children due to the lower bacterial burden of TB in children compared to adults 
(Marais and Pai, 2006). This does not mean that paediatric urine has no applicability in the 
clinical setting, instead it indicates that a specific diagnostic test for children are needed.  
It is known that urine is a valuable source in biomarker discovery studies for diagnostic 
purposes. Urine contains several thousand proteins and is a less complex sample than 
plasma which contain more than 10 000 core proteins (Wasinger, Zeng and Yau, 2013). 
Liquid chromatography (LC) couples to mass spectrometry (MS) remains the analytical 
technique of choice as it provides the best sensitivity, selectivity and identification 
capabilities for biofluids (Spahr et al., 2001). MS enables direct identification of molecules 
based on the mass-to-charge ratio as well as fragmentation patterns. Thus, it fulfils the role 
of a qualitative analytical technique with high selectivity (Urban, 2016). The most widely used 
strategy of tandem LC-MS is known as shotgun or discovery proteomics. For this method, 
the MS instrument is operated in data-dependent acquisition (DDA) mode, where fragment 
ion (MS2) spectra for selected precursor ions detectable in a survey (MS1) scan are 
generated (Mann et al., 2011). The resulting fragment ion spectra are then assigned to their 
corresponding peptide sequences by sequence database searching (Kapp and Schütz, 
2007).  
In data-independent acquisition (DIA) mass spectrometry (MS), the instrument 
deterministically fragments all precursor ions within a predefined mass-to-charge (m/z) range 
and acquires convoluted product ion spectra, containing the fragment ions of all concurrently 
fragmented precursors. By rapidly and recursively scanning through consecutive, adjacent 
precursor ion windows, termed swaths, the full precursor ion m/z range of tryptic peptides is 
covered and consequently, fragment ion spectra of all precursors within a user defined 
retention time (RT) versus m/z window are recorded over time. This results in a data set that 





represents a digital recording of the protein sample analysed (Gillet et al., 2012). The term, 
“DIA” was originally coined by Venable et al. in 2004 to contrast with DDA. Initially data 
generated by DIA was analysed using similar database search engines as for DDA data, but 
the multiplexing made it difficult to deconvolve the spectra (Venable et al., 2004). DIA data 
analysis now rely on spectral library searching (Egertson et al., 2013). Alternative 
approaches to spectral library searching exists, such as Walnut/PECAN (Searle et al., 2018), 
Spectronaut (Bernhardt et al., 2012) and DIA-NN (Demichev et al., 2020). With the use of 
DIA-Umpire (Tsou et al., 2015) it is also possible to generate pseudospectra.  
 
The goal of this review is to introduce the reader to the current two most widely used 
analytical acquisition modes, DDA and DIA MS. We firstly discuss the diagnostic challenges 
in paediatric TB and the usefulness of urine as a source for protein biomarker discovery.  
2.3. Paediatric Tuberculosis 
 
The risk of children infected with active TB increases with exposure to adults with TB, age, 
human immunodeficiency virus (HIV) infection and undernourishment (Holmberg, Temesgen 
and Banerjee, 2019). A world map designed in 2018, shows the percentage of all new and 
relapse TB cases that occurred in children younger than 15 years of age. East Africa is 
observed to have the highest proportion of recorder TB cases (>10%) in children (Figure 
2.1). Each region has different risk factors associated with the disease. For example, in 
South Africa the presence of maternal tuberculosis in combination with human 
immunodeficiency virus (HIV) is associated with a higher number of TB case notifications. In 
Kenya the problem of undernourishment contributes to a higher number of TB cases. Both 









Figure 2.1. Percentage of new and relapse TB cases that were children (aged <15) 
(World Health Organization (WHO), 2019). 
Whereas sputum is the specimen of choice for diagnosis of pulmonary TB in adults by 
microscopy, culture, or molecular methods, it is difficult to collect adequate respiratory 
specimens in young children (<7 years of age). This challenge, together with the 
paucibacillary nature of most pulmonary TB in children leads to a very low sensitivity 
currently available methods for TB in children (Marais and Pai, 2006). As a result, paediatric 
TB is often missed or overlooked due to non-specific symptoms (Schaaf et al., 2010). The 
diagnostic challenge limits the ability to conduct research on TB in children (Newton et al., 
2008). Proper disease management will require development of affordable and sensitive 
diagnostic tests that are not sputum-based.  
Currently TB-endemic countries rely on the TB skin test, also called the Mantoux tuberculin 
test (TST), together with symptoms and where available, chest radiographs, to diagnose TB 
in children. A TB skin test involves injecting tuberculin purified protein derivative (PPD) into 
the skin. The reaction is identified as palpable induration (hardness) at the site of injection, 
however, this response only indicates hypersensitivity and can be positive in persons with 
asymptomatic (latent) TB infection as well as those with TB disease. Furthermore, the TST 
can be negative in a TB infected child due to severe malnutrition, HIV infection and 
immunosuppressive drugs like high dose steroids (South African National Department of 





Besides the diagnostic challenges, paediatric TB faces an under-reporting challenge as well. 
The incidence of paediatric TB is higher than the number of TB case notifications provided 
from WHO estimates of tuberculosis prevalence in 2010, especially for children younger than 
5 years of age (Dodd et al., 2014). Household contact management (HCM) could 
substantially reduce childhood disease and death caused by tuberculosis globally. More 
children can be diagnosed earlier if we implement HCM (Dodd et al., 2018). Results from 
this multi-cohort collaboration indicate that greater focus should be placed on the first 5 
years of life as a period of high risk of progression from tuberculosis infection to disease. 
Despite the effectiveness of preventive therapy, most cases occurred within weeks of 
initiation of the contact investigation. Although contact tracing is a high yield means for early 
case detection, many children are reached too late to prevent disease. Earlier diagnosis of 
adult cases or community-wide screening approaches in children might be needed to 
improve prevention of tuberculosis in children (Martinez et al., 2020) together with improved 
diagnostic testing. 
2.4. Urine proteomics 
 
Urine proteomics has become a popular subdiscipline of clinical proteomics because urine is 
an ideal source for the discovery of non-invasive disease biomarkers (Beasley-Green, 2016). 
The human kidney (Figure 2.2) is made of functional units called nephrons. The nephrons 
are divided into two compartments, the glomerulus that filters plasma yielding urine and the 
renal tubule that reabsorbs the urine. Therefore, urine may contain important information, not 
just about the kidneys and urinal tract but also about distant organs due to this glomerulus 
filtration. The analysis of the urinary proteome might therefore allow the identification of 
biomarkers of diseases, even diseases not related to renal dysfunction. Urine from a healthy 
individual contains a significant number of peptides and proteins (Decramer et al., 2008). By 
contrast, blood serum has been the preferred biofluid due to the high abundance of 
information from blood serum for the discovery of biomarkers. However, the relatively high 
concentration of the most abundant serum proteins, as well as their wide range of protein 
concentrations, spanning at least nine orders of magnitude, often limit the study of serum 
biomarkers (Kentsis et al., 2009). The use of MS methods has shown promising insights into 
the human physiology as it reflect the changes in a human body (Azarkan et al., 2007; 






Figure 2.2. Urinary proteome. 70% of the urinary proteins and peptides originate from the 
kidney and the urinary tract, whereas the remaining 30% originates from the circulation. 
Although these promising insights can be positively correlated to disease status, it is 
noteworthy to take into account the changes in protein and peptide concentrations due to the 
relationship between daily fluid intake and the intra-individual and inter-individual variability 
(Schaub et al., 2004). Therefore, highly powered clinical proteomics study could have no 
significant meaning due to the challenge of reproducibility introduced by physiological 
changes. Inter- and intra-proteome variability is a major challenge, which is common in most 
proteomic studies of biological fluids. A later study discussed the standardisation of MS-
method based on peptides generally observed within urine (Schiffer, Mischak and Novak, 
2006). Over the years various MS technologies have been developed with varying degrees 
of analytical performance in terms of mass resolution, reproducibility, selectivity, and 
sensitivity (Beasley-Green, 2016). However, molecular biomarkers have not become 
practical in clinics yet, and extensive attempts have been devoted to validating these 
molecular markers (Kalantari et al., 2015b). Once a clinal question has been identified, it is 
important that proper statistical methods are used to support the conclusion (Good et al., 
2007). It is expected that advances in analytical tools and software programs as well as 
accurate study design soon will improve sensitivity and specificity of available biomarkers 
(Kalantari et al., 2015b). Many single biomarkers do not hold up during the validation phase. 
It was proposed that a multimarker panel may achieve high sensitivity and specificity with the 
same general criteria used for single markers (Fliser et al., 2007; Barratt and Topham, 
2007). 
To develop urine protein biomarkers as diagnostic tools, clinical usefulness must be verified 





made to characterize more urinary proteins in recent years, but few have focused on the 
analysis throughput and detection reproducibility. In a study by Lin et al. the high abundance 
blood proteins in the plasma proteome had negative effects on the actual analytical depth. 
Only after extensive peptide fractionation and 10 hours of MS time could the proteome be 
mapped in-depth. This give blood a disadvantage in comparison to urine in clinical 
proteomics. Urine is less complex and it has been suggested to replicate the workflow in this 
study to extensive urine proteome profiling and clinical relevant biomarker discovery (Lin et 
al., 2018). An adequate number of samples would allow for a generalisable result.  
 
Often in case-control studies, discoveries start with a selection of cases (with disease) and 
controls (without disease). Selection bias can occur at biomarker development, sample 
acquisition and handling, participant selection, the assay process and at the statistical 
analysis and interpretation of results stage (Zheng, 2018). Therefore, a totally random 
selection of samples would be ideal, which allows us to assume that the variability observed 
in the selected samples represents the biological variability in the population and that the 
sample mean reflects the “intended use population” mean (Figure 2.3). Random selection is 
the ideal; however, it is often not possible to exclude all biases and confounding factors from 
samples. Therefore, these factors must be controlled for in sample selection and in data 
analysis. The clinical aim must be carefully determined. Formulate a “molecular hypothesis” 
and make sure the analysis method can quantify the essential molecules at the expected 
level. The primary objective should be defined considering sampling and performance of the 






Figure 2.3. Sample selection will give estimates for the whole population. 
 
2.5. Shotgun proteomics 
 
Shotgun proteomics has developed as a robust and sensitive approach to identifying 
proteins in a complex biological sample. In this data dependent acquisition (DDA) approach, 
a sample for analysis is prepared by digesting a protein mixture with trypsin to yield a 
mixture of peptides. The peptides are then loaded on a liquid chromatography column in-line 
with a mass spectrometer (MS). The identity of thousands of peptides is provided during 
database searching, which have proven invaluable for automating the characterization of 
uninterpreted tandem mass spectra and facilitating high-throughput proteomics; however, 
there remains room for improvement. The database search algorithms make assumptions on 
where the peptide fragments and also which peptide bonds are most likely to break, allowing 
fragment intensity predictions. In this way most peptides are correctly identified, however, 
better prediction of peak intensities could optimise peptide identification. Protein 
modifications are identified by the algorithms looping over all possible combinations of 
modified and unmodified residues in a peptide sequence. The efficacy of this looping comes 





algorithms down. Search algorithms making use of previously characterized mass spectra 
could address both limitations (Frewen et al., 2006a).  
 
Nevertheless, sampling of complex proteomes by shotgun proteomics are incomplete and 
this is observed by assessment of protein and peptides by spectral counting approaches. 
One such approach is IDPicker, a GUI that stores query information from shotgun proteomes 
in a cross-platform SQLite file format. DDA remains to pose challenges when attempting to 
compare proteomes from different biological states based on spectral counting approaches 
(Li et al., 2010). DDA is a powerful technique for the identification of proteins and peptides in 
a complex mixture; however, DDA become less effective in detecting all peptide in a mixture. 
To detect a peptide, the MS/MS data must be queried for the signal specific to that peptide. 
Because the MS/MS data in a DDA experiment is sampled stochastically, by which a 
different subset of the available precursor ions is sampled in each subsequent analysis 
(Domon and Aebersold, 2010), it is impossible to determine whether a peptide with no 
matching spectra is non-detectable, or detectable but not sampled by MS/MS (Egertson et 
al., 2015). Due to this reason, a data independent  acquisition (DIA) approach was later 
developed (Venable et al., 2004). 
 
2.6. Quality control in DDA 
 
In any discovery proteomics experiment, as many spectra as possible are generated through 
tandem mass spectrometry (MS/MS). The generated spectral data is interpreted using 
various bioinformatics means. Unfortunately, despite the computational advances in the 
proteomics field, variability within results remains a challenge (Martens, 2013). The 
variability can stem from multiple sources. To achieve confidence in the obtained results and 
to ensure reproducible data, it is important to use quality control (QC) measures to monitor 
and control the existing sources of variability. This is especially important in long term multi-
site projects (Bittremieux et al., 2018). QuaMeter (Tabb, 2012) is an open-source tool that 
computes objective quality metrics for evaluating DDA experiments. The software accepts 
raw instrument data and identification data as inputs and outputs a tab-delimited file of 
quality metrics, which are interpreted using statistical methods. QuaMeter allows 
researchers to track sources of variability in routine practice in real time before critical 
samples are wasted (Ma et al., 2012). The current QC tools available are limited to DDA 
discovery experiments. These quality metrics cannot be directly translated to DIA 
experiments (Bittremieux et al., 2017). Efforts towards expanding QC to workflows such as 







2.7. Data-independent acquisition mass spectrometry 
 
Until now, research has focused on the highly abundant urinary proteins and peptides. 
Analysis of the less abundant and naturally existing urinary proteins and peptides remains a 
challenge (Beasley-Green, 2016). Less than a decade ago sequential window acquired 
theoretical MS (SWATH-MS) was introduced to complement DDA approaches such as 
shotgun discovery proteomics. The SWATH-MS approach is a data independent acquisition 
(DIA) method performed on a high-resolution mass spectrometer that records a complete 
recording of all fragment ions of the detected peptide precursors over chromatographic time 
in a sample. The data analysis depends on a priori assays, derived from fragment ion 
spectra of the targeted peptides that are best generated in the same high-resolution 
instrument used for SWATH-MS acquisition (Gillet et al., 2012). Using freely or commercially 
available software (OpenSWATH (Röst et al., 2014) or Skyline (MacLean et al., 2010) and a 
DDA-based library, SWATH-MS can be used to carry out protein quantification at 
performance metrics at a high throughput (Rosenberger et al., 2014). DIA was observed to 
surpass the protein and peptide identification abilities of DDA. In two studies, DIA 
experiments doubled the number of proteins and peptides identified compared to DDA 
where the use of a type-specific spectral library was preferred (Muntel et al., 2015; Bruderer 
et al., 2017).  
 
Library searching was first proposed as an alternative method to identify MS/MS spectra  in 
1998 (Yates et al., 1998), but only recently has it been recognized as a means to interpret 
data-independent acquisition (DIA) data. DIA has emerged as a more reproducible 
quantitative strategy than data-dependent acquisition (DDA), (Muntel et al., 2015; Li et al., 
2019) but it generally depends on acquisition of DDA data to build the spectral library. A 
common concern with the use of library searching is that peptide identification is limited to 
only the peptide spectra included in the library, so different approaches have emerged that 
combine library and database search results or that use more sophisticated library searches. 
Combining the effort of database searching and library searching in a dual search provides 
higher reproducibility of peptide identification and quantification without the need to generate 
new data for library searching (Fernández-Costa, Martínez-Bartolomé, D. McClatchy, et al., 
2020). High-throughput sequencing and protein prediction algorithms have provided 
adequate protein sequences for database searches. Likewise, spectral library searching was 
observed to improve identification and quantification using. The protein overlap of technical 
replicates in both DDA and DIA experiments was 30% higher with library-based 





Bartolomé, D. B. McClatchy, et al., 2020). Most proteomics studies rely on project specific in-
house spectral libraries. However, efforts towards creating a universal atlas database for DIA 
are being made (Tong et al., 2019). 
 
A recent study combined DDA and DIA in a single LC-MS/MS run and defined it as a data 
dependent and independent acquisition (DDIA) experiment. Using the retention time 
calibration curve from DDA data as a classifier for DIA extraction false-discovery rate (FDR) 
control more proteins could be detected with a smaller number of associated peptide 
compared to DDA and DIA methods (Guan et al., 2020). The current DIA-MS methods 
normally cover a wide mass range, with the aim to target and identify as many peptides and 
proteins as possible and therefore frequently generate MS/MS spectra of high complexity. In 
a study by Li et al. smaller windows shortened the computational analysis time of DIA data 
while it directly improved quantitation precision. The window size prediction was made using 
prior knowledge about the biological sample (Li et al., 2019). Collecting prior knowledge has 
shown to enhance the ability of DIA analysis and could lead to convergence of these 
methods. Including both the MS1 and MS2 level information has proven to increase the 
precision of the measurement for technical replicates. This also provides the ability to 
identify sources of technical variance by statistical modelling in turn improving the power of 




To date, limited work has been performed on the diagnosis of paediatric TB. It is difficult to 
collect sputum on demand from children younger than 7 years of age. As a result, children 
are often overlooked as a risk group. The risk of children infected with TB increases with 
exposure to adults with TB. The currently available methods to diagnose TB in children have 
low sensitivity. Urine is non-invasive and easily attainable in large quantities. Therefore, 
urine presents as an ideal source for mass spectrometry (MS) - based protein biomarker 
discovery for paediatric TB diagnosis. MS methods has shown promising insights into the 
human physiology as it reflects the changes in a human body and could reflect disease 
status. In many studies single biomarkers do not hold up during the validation phase. It was 
proposed that a multimarker panel may achieve high sensitivity and specificity with the same 
general criteria used for single markers. DDA is a powerful and most used analytical method 
for discovery proteomics; however, the MS/MS data in a DDA experiment is sampled 
stochastically, by which a different subset of the available precursor ions is sampled in each 





spectra is non-detectable, or detectable but not sampled by MS/MS. Due to this reason, a 
DIA approach was later developed. The ability to collect prior knowledge from DDAs ability 
to identify proteins and peptides has shown to enhance the ability of DIA analysis and could 
lead to the convergence of these technologies. Including both the MS1 and MS2 level 
information has proven to increase the precision of the measurement for technical replicates. 
This also provides the ability to identify sources of technical variances by statistical 








Evaluation of Quality Metrics for Data-Dependent Acquisition (DDA) discovery 
proteomics data and Data-Independent Acquisition (DIA) data acquired on a Q-
Exactive mass spectrometer (Thermo Scientific) 
 
Chapter 3 evaluates the quality metrics of DDA data, and comparative DIA data acquired on 
the same instrument in the same laboratory. In this study, QuaMeter “ID-Free” software and 
SwaMe software were employed to generate quality metrics for DDA and DIA human urine 
proteomics experiments, respectively. The use of these quality metrics identifies sources of 
variability through factor analysis. Technical variability can impact the reproducibility of an 
experiment and mask the true biological variability within a batch effect, thereby undermining 
the search for paediatric tuberculosis diagnostic markers.  
  
3.1. Materials 
• MSConvert GUI, part of the ProteoWizard library 
(http://proteowizard.sourceforge.net/download.html); 
• QuaMeter “ID-Free” executable, part of the Bumbershoot project 
(http://proteowizard.sourceforge.net/download.html), scroll down and select the 
platform “Bumbershoot Windows 64-bit tar.bz2”; 
• SwaMe Console executable, part of the Yamato framework 
(https://github.com/PaulBrack/Yamato); 
• RStudio Desktop (https://rstudio.com/products/rstudio/download/); 
• R version 4.0.2 (https://cran.r-project.org/bin/windows/base/). 
3.2. Equipment 
 
• A 64-bit computer with Windows 10 operating system, 8 GB of RAM, a quad-core i5 
processor and more than 50 GB of free disk space. 
3.3. Experimental Section 





237 DDA and 225 DIA raw instrument files were converted to mzML format (Deutsch, 2010) 
using the MSConvert GUI, a tool built on the ProteoWizard library (Kessner et al., 2008) with 
peak picking selected. The parameters used are provided in Table S3.1 of the 
Supplementary Material. For the DDA dataset, the “IDFree” QuaMeter software (Tabb et al., 
2014) was used to produce a list of quality metrics that are independent of identification 
success rates for MS/MS scans. The typical run time for one Q-Exactive raw DDA files less 
than 1 min per DDA file, largely consumed by the extraction of ion chromatograms. For the 
DIA dataset, a QuaMeter-based SWATH metric library called SwaMe software (Kriek, 
unpublished) was used to produce three different sets of metrics. The comprehensive set of 
metrics was used for further analysis. The typical run time for one Q-Exactive raw DIA file is 
less than 30 sec per DIA file. 
3.3.2. Data Visualization and Explorative analysis 
QuaMeter provides 44 identification-independent metrics to measure the performance in a 
single DDA experiment, while SwaMe produces three sets of metrics to measure the 
performance in a single DIA experiment. All metrics generated by QuaMeter IDFree are 
explained in the user manual (Tabb, 2012) and the metrics generated by SwaMe are defined 
in Table S3.2 of the Supplementary material. Robust principal component analysis (PCA) 
was used to visualize and explore the high dimensional metrics from QuaMeter and SwaMe, 
collectively (Ringnér, 2008) using R version 4.0.2 with the RStudio Integrated Development 
Environment (IDE).  In each set of metrics, a dates column was added in the international 
standard format YYYY-MM-DD. All the fractions of MS/MS precursor charges and the fastest 
measured frequencies for MS1 and MS2 collected in any minute (in Hz) in the QuaMeter 
metrics and the retention time duration and swath size differences in the SwaMe metrics 
were omitted from PCA analysis due to the low variance contribution of these metrics. A 
subset consisting of only numeric values were used for PCA analysis.  
 
PCA finds a linear combination of rescaled metric values that maximizes the amount of 
explained variability among the experiments as principal component one then it finds the 
linear combination of rescaled metric values that maximizes the amount of remaining 
variability explained as principal component two. The contribution to variance per component 
simplifies to nine PC scores, visualized with scree plots shown in Figure S3.1 of the 
Supplementary Material, where component 1 and 2 (PC1 and PC2) accounted for the most 
variance. PC1 and PC2 were visualized and samples were grouped by date to assess for 
batch effect. Factor analysis was used to identify the covariance relationship between the 





individual sources of variability in the data. The factor analysis is carried out on the factor 
(correlation) matrix estimated using the robust quality metrics.  The loading matrix rotates 
under the varimax criterion (Kaiser, 1958), where each factor successively accounts for the 
maximum variance of the squared loadings (squared correlations between variables and 
factors). This resulted in a high factor of loadings for a smaller number of variables and low 
factor loadings for the rest, which makes it easier to identify the variables (metrics) 
contributing to variance within the data.  
3.3.3. Dissimilarity 
 
The dissimilarity between a pair of DDA and a pair of DIA, respectively, was measured using 
the Euclidean distances between the PCA coordinates for a DDA. Mathematically, the 
dissimilarity between two dimensional coordinates 𝑥1 and 𝑥2 is  
 
√(𝑥11 − 𝑥21)
2 +  (𝑥12 − 𝑥22)




Equation 3.1 was used to calculate the distance table along with a distance matrix was 
generated. The distance table and distance matrix were rearranged into one vector, and the 
median Euclidean distance value was calculated per run to indicate dissimilarity, where the 
larger the dissimilarity value was, the less similar the experimental run was to the other 
experiments. Boxplots visualized the number of outliers in the DDA and DIA dataset. All 
values above the top-whisker were labelled as outliers. 
 
3.4. Results and Discussion 
3.4.1. Comparison of DDA and DIA Performance Metrics 
Despite the recent advances in proteomics technology, the results of the large-scale 
experiments were still subject to variability. The presence of source of variability placed 
emphasis on the performance of the instrument used for data acquisition. Variability can 
stem from multiple sources such as the computational interpretation, the stochastic nature of 
the different stages within an LC-MS experiment and the presence of contaminants. On the 
other hand, longitudinal variability arises from instrument drift and sample degradation 





attention identifying sources of variability called quality control (QC) is an important 
preventive maintenance to give researchers confidence in their acquired results and to not 
suffer exaggerated claims.  
 
Figure 3.1. An Ishikawa diagram (non-exhaustively) shows the major sources of 
variability in a typical LC-MS experiment. These sources variability will impact the results 
and should be considered in a comprehensive DDA or DIA workflow (Bittremieux et al., 
2018). 
A need for freely available, open source, automated, and easy-to-use QC software tool was 
clear (Martens, 2013). In 2014, Tabb et al. developed an open-source software QuaMeter 
“IDFree” that can generate a set of quality metrics directly from raw spectral data. This 
allows for quality metrics to be generated within a few minutes of a DDA run being 
completed (Bittremieux et al., 2017). Previously, identification free metrics were limited to 
DDA experiments, however, in 2019 QC efforts expanded using a QuaMeter-based SWATH 
metric library tool called SwaMe to generate quality metrics (Kriek, unpublished) for DIA 
workflows. Multivariate statistical methods are important in performance evaluation due to 
the complex processes of routine experiments. The quality metrics represents an integrated 
group of measures on these processes (Tabb et al., 2014). 
In this study, multivariate statistical methods were used to analyse the quality metrics. 
Robust multivariate statistical methods can produce insights on the laboratory, sample and 
experimental variability assessment of large-scale experiments (Tabb et al., 2014). Principal 
Component Analysis (PCA) is a widely used mathematical algorithm that reduces the 





accounted for by each component (Ringnér, 2008). The first two components of the robust 
PCA (PC1 and PC2) for the QuaMeter IDFree metrics from DDA data and PC1 and PC2 for 
the PCA for the SwaMe undivided metrics from DIA data are visualised in Figure 3.2. The 
PCA plots represent a snapshot for data exploration between these two modes. The DDA 
experiments are grouped together by date for 13 consecutive days (Figure 3.2.A), whereas 
the DIA experiments are grouped by date for 14 consecutive days which were subjected to 
experiment eight months after the DDA experiments were done (Figure 3.2.B). During the 
eight-month period sources of biological variability such as degradation, modification and 
freeze thawing could have affected the sample stability over time.  
The sample grouping; however, shows that there was no one day that separated from the 
rest of the experiments based on the quality metrics for DDA experiment and DIA 
experiments, but rather indicated that runs that appear to separate from the bulk of the data 
that were not run sequentially i.e. were random but not systematic events. One needs to also 
take the rest of the principal components into account to conclude which runs are to be 
considered samples not meeting the quality control criteria. In this case, for the DDA data, 
the first two principal components account for 54.0% and 12.5% of the variability in the 
QuaMeter IDFree metrics, respectively. For the DIA dataset, the first two components 
account for 92.4% and 4.7% of the variability in the SwaMe metrics, respectively. Adding a 
third component would describe 9.0% additional variability for the QuaMeter metrics and an 
additional 3.0% for the SwaMe metrics. Secondly, PC1 and PC2 for the SwaMe metrics 
account for a larger proportion of variability compared to PC1 and PC2 for the QuaMeter 
metrics, which may be due to SwaMe only producing the 10 comprehensive metrics 
compared to the 44 metrics produced by QuaMeter IDFree. Therefore, these ratios cannot 
be directly compared. To understand the underlying process that influences experimental 
performance, exploratory factor analysis was done (Tabb et al., 2014). The technique 







Figure 3.2. PCA of quality metrics. QuaMeter IDFree metrics were generated from DDA 
samples (A) and PCA of SwaMe undivided metrics were generated from DIA samples (B) 
collected on a Thermo Q-Exactive mass spectrometer. Each dot represents a sample. 
Samples were grouped by date denoted by a different colour.  
In the DDA experiments in Figure 3.3.A. the loadings accounting for the greatest variability 
were associated with the number of MS1 scans collected (MS1.Count), the first quartile and 
the median of the MS1/MS1 scan peak counts (MS1.Density Q1 and Q2), the ratio of the 





one scan to the next (MS1.TIC.Change.Q2 and Q3). In the DIA experiments in Figure 3.3. B. 
the loadings accounting for the maximum variability were associated with how many MS/MS 
scans were collected (MS2.Count) and the IQR for the number of ions detected in all MS2 
scans (MS2DensityIQR). The distribution of density and the number of scans appeared 
important to the variability for both DIA and DDA, although in DDA they were all related to 
MS1, whereas in DIA they were all related to MS2. One might conclude that only DDA data 
are more influenced by MS1 signals than DIA, but investigation of the SwaMe metrics 
reveals that none of them pertain to MS1 TIC values.  TIC metrics for SwaMe can be 
computed using the retention time (RT)-division calculator within the Yamato framework, but 
the RT-divided metrics were not considered for PCA. There is also no metric for MS1-
Density changes in SwaMe, only the MS2-Density changes are observed. There is a metric 
for MS1 Count, yet in the DDA data it is observed as a source of variability while it is not in 
the DIA data. The examination of loadings revealed that combinations of key metrics can be 
used to monitor variability in the data, however, different combinations are observed for DDA 
data compared to DIA data. To understand what each quality metric signifies requires 






Figure 3.3. Loadings of the quality metrics under the Kaiser varimax criterion. The 
biplots shows the relationship between the principal components and a set of the QuaMeter 
metrics (A) and a set of the SwaMe metrics (B). 
3.4.2. Dissimilarity Assessment 
To comprehensively investigate the possible outliers a dissimilarity assessment was done as 
explained in the experimental section. The clustering of the outliers indicates their similarity. 





the robust PCA coordinates for each pair of LC-MS/MS experiments. Euclidean distance is 
one metric to assess dissimilarity by comparison of only two experiments. The Euclidean 
metric is the most common and intuitive measure of distance. Thus, any abnormal 
experiment (outlier) will influence only the dissimilarity measures that include that 
experiment.  Distance metrics characteristically yield less accurate estimates than actual 
measurements, but each metric provides a single model of travel over a given path. 
Euclidean distance tend to underestimate the distance while a measure such as Manhattan 
distance tend to overestimate the distance (Shahid et al., 2009). Due to the limitations of 
distance metrics, unlike actual measurements, it can be directly used in spatial analytical 
modelling.  
 
Figure 3.4. A and B visualise the distribution of the medians of the distances of experiments 
to PCA, where samples above the top-whisker were classified as outliers. In this case, the 
DDA dataset of 237 samples had 18 outliers with a distribution median of 4.4 and an inter-
quartile range (IQR) of 1.8 and the DIA dataset of 225 samples had 14 outliers with a 
distribution median of 2.4 and an IQR of 1.0 (Supplementary Table S3.2) these outliers were 
highlighted in blue to visualise the points in space on the PCA plot for DDA and DIA 
experiments (Figure 3.5.A and Figure 3.5.B). The median values indicate that there are 
differences between groups and the larger IQR in the DDA dataset indicates that the data is 
more dispersed. The level and spread of the dissimilarity between experiments are 
consistent in the DDA dataset as well as in the DIA dataset. Due to the differences in the 
quality metrics generated, the QC of the two experiments cannot be directly compared. 
These results show that using the same instrument in the same laboratory greatly increase 
the reproducibility and repeatability of the experiments irrespective of the start time of the 
experiments. The samples identified as outliers were excluded from the biomarker discovery 
phase; however, researchers can decide to re-run these samples for inclusion in 







Figure 3.4. Boxplots show the distribution of the medians of the Euclidean distances 







Figure 3.5. PCAs with all samples labelled. The DDA samples had 18 outliers highlighted 








Comparative samples were analysed on a Thermo Q-Exactive mass spectrometer in DDA 
and DIA mode. Quality metrics were successfully produced from the spectrum files in mzML 
format for all experiments. The QuaMeter “IDFree” metrics for DDA experiments and SwaMe 
undivided metrics for DIA experiments examines the signals recorded in the experiments 
that indicates variability. Researchers need to know if batch effects exist under either 
instrumental paradigm; if batch effects are prominent, the comparability within these 
experiments may be compromised. This study used Euclidean distances derived from PCA 
to recognize when a subset of experiments in a large set were distant from the main body of 
the data due to unusual instrument condition. The batch effects were minimal in the 
experiments. The individual sample point that appear furthest from the clustered sample 
points were not sequentially run, suggesting a common cause to their disparity.  
The relationship between factors and a set of quality metrics to identify the sources of 
variability to explain the possible outliers. The distribution of density and the number of 
scans appeared important to the variability for both DIA and DDA, although in DDA they 
were all related to MS1, whereas in DIA they were all related to MS2. TIC impacted only the 
DDA data but not the DIA, this was possibly due to SwaMe comprehensive metrics not 
containing any TIC metrics. There was also no metric for MS1-Density changes in SwaMe, 
only the MS2-Density changes were observed. SwaMe has a metric for MS1 Count, yet in 
the DDA data it is observed as a source of variability while it is not reflected in the DIA data 
as well.  
Traditional outlier analysis was done with dissimilarity assessment. The different median 
values indicate that there are differences between DDA and DIA samples. The samples 
identified as outliers in DDA data were not comparable with the samples identified as outliers 
in the DIA data. This not an unexpected result due to fewer quality metrics computed by 
SwaMe on DIA. The samples identified as outliers were excluded from the biomarker 
discovery phase (discussed in Chapter 5). Future recommendations would be to exclude the 
outliers and then redo the PCA to identify whether the method detects new possible outliers 
with the same sources of variability. It would also be useful to develop quality control models 
for dynamic performance monitoring that can allow for systematic incorporation of the 







An Optimised Data-Independent Acquisition (DIA) analysis method leveraging 
Shotgun Proteomes Using Open-source software 
 
Chapter 4 describes the use of a data independent acquisition (DIA) workflow on a Q-
Exactive mass spectrometer for the detection and quantification of peptides using the 
Skyline Targeted Proteomics Environment (freely available on-line at MacCoss Lab Software 
https://skyline.ms/project/home/software/Skyline/begin.view). In this study, a targeted DIA 
data analysis method was optimized leveraging a comparative data dependent acquisition 
(DDA) data set. The DDA data set was subjected to database searching using the 
MSGFPlus and MSFragger search engines, respectively. The protein assembly was handled 
by the IDPicker algorithm. To allow for stable and accurate prediction of peptide retention 
times, the data analysis method employed a retention time database generated using 
standards representing the most abundant peptides commonly found in human urine 
proteomes. Experiment-based spectral libraries were created to support peptide standards 
selection, however, the targeted DIA data analysis method relied on a comprehensive 




• Raw mass spectrometry data from 237 DDA proteomics experiments;  
• Raw mass spectrometry data from 225 DIA proteomics experiments; 
• Philosopher toolkit executable version 3.2.9 
(https://github.com/nesvilab/philosopher/releases/tag/v3.2.9) scroll down and select 
“philosopher_v3.2.9_windows_amd64.zip”; 
• Java Runtime Environment version 1.8 (required for MSFragger and MS-GF+ jar 
files) (https://java.com/en/download/windows-64bit.jsp); 
• MSFragger Software, version 3.0 (https://bit.ly/2z6dzXa); 
• MS-GF+ Software, release 2020.03.14 
(https://github.com/MSGFPlus/msgfplus/releases); scroll down and select 
“MSGFPlus_v20200314.zip” 
• Microsoft .NET Framework 4 (https://www.microsoft.com/en-
us/download/details.aspx?id=17851); 





• Skyline Software version 20.1 
(https://skyline.ms/wiki/home/software/Skyline/page.view?name=SkylineInstall_64_2
0-1); 
• RStudio Desktop (https://rstudio.com/products/rstudio/download/#download); 
• R version 4.0.2 for Windows (https://cran.r-project.org/bin/windows/base/). 
4.2. Equipment 
 
• A 64-bit computer with Windows 10 operating system, 8 GB of RAM, a quad-core i5 
processor, and more than 50 GB of free disk space. 
4.3. Experimental Design 
4.3.1. Identification of peptides by Sequence Database Searching  
In classic shotgun proteomics, the data are recorded using data dependent acquisition 
(DDA). Traditional database searching identified peptides from 237 DDA raw instrument 
files. Database searching matches the tandem mass spectra with a database of all possible 
peptide sequences predicted within a proteome sequence and provides scores for each 
assignment (Kertesz-Farkas et al., 2012). For the first search, MS-GFPlus algorithm (Kim 
and Pevzner, 2014) was used to generate spectral vectors, and in this case, search the 
Ensembl protein database to compute rigorous scores for peptide-spectrum-matches 
(PSMs) and estimate false discovery rate (FDRs). In a second re-search, the Philosopher 
tool was employed through the command line to download protein sequences from UniProt 
Knowledgebase (UniProtKB). This generated a human UniProtKB database with common 
contaminants and decoys added. The ultrafast search engine, MSFragger (Kong et al., 
2017) was used here. The command line executions for the search engines are provided in 
Table S4.1 of the Supporting Material.  
To further boost the performance, IDPicker (Ma et al., 2009) was used to graphically 
interpret the search results creating one protein assembly file (idpDB) returning identification 
rates. This tool uses the Target-Decoy Approach (TDA) to impose a peptide spectrum match 
false discovery rate at a pre-determined threshold of 5%. It is expected that at most 5% of 
the returned identifications would be false positives (Jeong, Kim and Bandeira, 2012). This 
inference tool is useful in producing protein and peptide pivot tables which allows the peptide 







4.3.2. Creating the target Protein and Peptide List  
For the next step, the R programming language was used to read the protein table from the 
ultrafast search with MSFragger. For the proteins identified, a count of how many spectrum 
files matched a protein at least once was computed as a score defined as the RS-score 
using a for loop. The tidyverse R library provided functions to sort proteins by their RS-score 
in descending order, breaking ties by sorting by descending numbers of filtered spectra. The 
top protein identifiers based on RS-score greater than N divided by two from this list were 
kept. Thereafter the non-redundant peptide table from IDPicker was read into R, a second 
for loop was used to compute the RS-score for each peptide. The peptides were sorted by 
RS-score in descending order, breaking ties by sorting by descending numbers of filtered 
spectra. For each protein identifier in the list, a set of five peptide sequences matching each 
protein identifier were pulled out. The final list of the top protein identifiers with their top five 
matching peptides sequences based on a high RS-score were used as the targets in the 
targeted DIA analysis method.  
4.3.3. Spectral Library Generation 
BiblioSpec software package (Frewen et al., 2006b) is a built-in tool in the Skyline software 
(MacLean et al., 2010) to create and search experiment-based tandem MS spectral libraries. 
The tool was used to create two custom spectral libraries using the 237 DDA raw files as 
input along with the MS-GF+ search outputs and MSFragger search outputs, respectively. 
Spectral library information was provided from the Steen laboratory who generated a 
comprehensive human urine protein library using the closed-source software, Spectronaut 
(Bernhardt et al., 2012). From this pre-assembled library, an assay library in the BiblioSpec 
format was generated.  
4.3.4. Standard Calibration Peptides Selection 
Using the tables produced by IDPicker, the two most abundant human urinary proteins were 
selected. For each protein, twelve peptides sequences were pulled out based on their RS-
score. These peptide sequences were imported in Skyline along with the spectral library 
generated using the 237 DDA raw instrument files and the outputs from the MSFragger 
search. An initial integration was done using all DIA raw instrument files to extract 
chromatograms for the 24 peptide sequences across all files. Skyline predicted retention 
times based on the sequence-specific retention calculator (SSRCalc) as well as observed 
retention times for the 24 peptide sequences across all DIA raw files. To select only twelve 





spread across a wide RT range while the observed retention times should not surpass an 
one-minute variability interval across all DIA raw files (Escher et al., 2012). Appropriate 
charts were made using ggplot2 and ggpubr in R to visualize the predicted and observed 
retention times. A second selection criterion was that a selected peptide must have intensity 
values across all DIA files. For this, the R-package MSstats was used to generated 
intensities for the peptide sequence across all DIA files. The final list of twelve peptides were 
used to create an iRT database file. 
4.3.5. Targeted DIA data analysis 
The methods and results described in the preceding sections were all used to evaluate the 
tools to be used in the analysis of DIA data leveraging from DDA data. The final method 
used a target peptide list that was created using the ultrafast MSFragger database search 
engine with the commonly used UniProtKB. Subsequent protein inference was done with the 
IDPicker algorithm. The comprehensive human urine spectral library was used to inform DIA 
chromatogram integration. To ensure accurate and stable RT prediction in the DIA analysis, 
twelve calibrant peptide standards were generated. The Skyline settings are provided in 
Table S4.3 of the Supporting Information. All DIA raw data file was imported into Skyline to 
extract chromatograms for quantification.  
4.4. Results and Discussion 
4.4.1. Sequence Database Searching 
The search with MS-GF+ yielded 52 186 peptide spectra while the search with MSFragger 
yielded 44 770 peptide spectra with 39 289 (68.1%) peptides shared in the shotgun 
experiment (Figure 4.1). These search results emphasize that when different combinations 
of tools are employed the capability of data analysis vary widely due to the different ways in 
how these algorithms score the peptide-spectrum matches (PSMs) which could inherently be 
a ranking problem (Frank, 2009). Using the MS-GF+ search engine, IDPicker could infer 
more peptides compared to the MSFragger search strategy. MS-GF+ uses a probabilistic 
model and computes rigorous E-values (score) giving the tool the ability to be used on 
diverse types of spectra, instruments and methods (Kim, Gupta and Pevzner, 2008, Kim and 
Pevzner, 2014). On the other hand, MSFragger has proven to be particularly useful for large-
scale unbiased detection of post translational modifications (Kong et al., 2017).  
The fragment-ion indexing allowed MSFragger to identify the PSMs in significantly less time 
compared to MS-GF+. However, the scoring system used by MS-GF+ could be giving the 





used by MSFragger. For the MSGF+ search, the Ensembl database was used; however, 
UniProtKB provides annotations with a minimal level of redundancy through human input or 
integration with other databases making it the predominantly used database for researchers 
(Xu and Xu, 2004, Chen, Huang and Wu, 2017). The UniProtKB was used to match the 
MSFragger search results, which provides the accessions most used between laboratories. 
The UniProt database matches the database employed by the Steen laboratory. For 
comparable accessions, these search results were used for further analysis. 
 
Figure 4.1. Venn diagram shows the relationship between search engines. The MS-
GF+ search engine identified more peptides than the MSFragger search. 
4.4.2. Target Peptide List Generation 
The DIA data analysis method used zooms in on the protein and peptide targets selected 
post data collection. The DIA data analysis method used here rely on the ability of shotgun 
proteomics (DDA-based) to detect all component peptides for targeted data analysis. From 
the protein table of 2245 proteins, a set of the top protein identifiers was selected. The 
number of samples containing spectra identified to each protein was computed. The 
tidyverse programming paradigm for crafting code in R was installed to sort the protein list 
by RS-score in descending order, breaking ties by sorting by descending numbers of 
overall spectra. A total of 590 proteins were selected. From the non-redundant peptide list, 
a set of 5 peptides were pulled out that match to the 590 proteins resulting in 2950 
peptides. Proteins with less than 3 peptides were removed, resulting in 514 proteins and 
2662 peptides in the target list. There is an intrinsic limitation caused by the stochastic 
nature of shotgun proteomics (Faria et al., 2017), therefore employing a refined data 
analysis approach could increase the sensitivity of the search for diagnostic markers. 





Traditional database searching algorithms are built on the assumption that each MS/MS 
represents the fragments of an individual peptide rather than containing the fragments of 
many peptides that were co-fragmented, therefore it cannot deconvolve the multiplexed 
peptide spectra from DIA (Noble and MacCoss, 2012). Alternative approaches such as DIA-
Umpire or PECAN exist to query MS data acquired in DIA mode without the need of a 
spectral library, but studies have been proven them to be less sensitive compared to using a 
spectral library (Navarro et al., 2017, Ting et al., 2017 , Tsou et al., 2015). Thus, DIA data 
analysis relies on spectral libraries instead to collect previously identified spectra, then 
create a reference library to identify spectra. The query spectra are compared to references 
in the library to find the ones that are most similar. A dot product metric is used to measure 
the degree of similarity, which distinguishes correct from incorrect identifications.  
In this study, the BiblioSpec software package (Frewen et al., 2006b) was used to create two 
experiment-based spectral libraries using the 237 DDA raw instrument files and the MS-GF+ 
search results and the MSFragger search results as inputs, respectively. Compared to the 
results from IDPicker, where the MS-GF+ database search identified more peptides than 
MSFragger database search, the spectral library creation search detected 35 981 unique 
peptides through the MS-GF+ search and 40 404 unique peptides through the MSFragger 
search. Although MSFragger identified more unique peptides, the peptides came from a 
smaller set of peptides overall. A study by Frewen et al. (2006) confirms this finding by 
showing that spectral library searching increases the number of peptides that can be 
identified compared to database searching. The study also points out that a large spectrum 
library has a very small reduction in sensitivity over a small spectrum library. It is known that 
with database searching the use of a different size FASTA files can affect the false discovery 
rate results. However it is currently unknown whether the size of a spectral library can result 
in a variance of the true positive rate in SWATH extraction (Zi et al., 2014). The FDR is an 
estimate from the best peak group per peptide query within one run, independent from the 
other runs acquire during the same experiment. It has been demonstrated that the FDR 
should thus be controlled at the peptide query-, peptide- and protein-level in peptide-centric 
scoring workflows applying comprehensive spectral libraries (Rosenberger et al., 2018). 
One set of MS/MS spectra for the peptide, AAAATGTIFTFR++ is shown in Figure 4.2 to 
visualise the intensity differences of the fragment ions between libraries. The quality and 
coverage of the spectral library is critical for peptide identifications, however the availability 
of open spectral libraries that can be used to process SWATH data is limited, therefore most 
users create their project specific libraries in-house. Spectral information was provided by 
the Steen laboratory who created a comprehensive human urine spectral library using 





format by Brendan MacLean (developer of Skyline MS). The assay library contained 56 697 
unique peptides detected with higher precursor ion intensities compared to the experiment-
based libraries. In Figure 4.2.A we can observe how the library does not measure the 
intensities for the b-ions in the lower m/z range, however higher intensities are recorder for 
the y-ions that are detected. This is because the Spectronaut KIT spectrum is normalised so 






Figure 4.2. Three spectral libraries. The pepXML files from the MSFragger search along 
with the DDA instrument files (A) and the mzIdentML files from the MS-GF+ search along 





Spectronaut library generated using pooled urine samples was formatted to a BiblioSpec 
format (C). 
4.4.4. Standard Calibrant Peptide Selection Process 
Targeted analysis of data-independent acquisition (DIA) data is a powerful mass 
spectrometric approach for comprehensive, reproducible, and precise proteome 
quantification. It requires a spectral library, which contains all considered peptide precursor 
ions with empirically determined fragment ion intensities and their predicted retention time 
(RT). RTs, however, are not comparable on an absolute scale, especially if heterogeneous 
measurements are combined, therefore index-based retention times (iRTs) have been 
employed (Bruderer et al., 2016). iRT is a technique for storing calibrated, empirically 
measured peptide retention times in a library for future use in retention time prediction for 
scheduled acquisition and peak identity validation.  The iRT concept has been implemented 
in Skyline using the sequence-specific retention calculator (SSRCalc) with 100-Å pore size 
C18 columns (Krokhin, 2006). In this study, commercially available synthetic standard iRT 
peptides were not spiked into samples during preparation. Thus, standard calibrant peptides 
were selected post data collection. 
A method based on lookups of previous registered retention times were employed for the 
DIA analysis method. From the IDPicker protein pivot table, the two most abundant proteins, 
human serum albumin and uromodulin were selected based on their RS-score. A total of 24 
peptides, 12 per protein were pulled out from the peptide pivot table based on a high RS-
score using R programming language. The sum of 24 peptides were imported into Skyline as 
target peptides while only 23 peptides match to the spectral library. All DIA raw file were 
integrated into Skyline and the peptide retention results were exported. Using the R-package 
MSstats, the intensities for each fragment ion for each peptide were extracted. This 
information provided a criterion to select the 12 standard calibration peptides from. The 
criteria require a wide retention time range with minimal retention time variability and 
consistent intensities across all DIA raw files (Escher et al., 2012).  
Each peptide sequence was assigned to a number label shown in Table S4.2 of the 
Supporting Material to make visualisation easier. The dot chart shows the wide range of 
predicted retention times for the 23 peptides. Peptide 15 from uromodulin and peptide 8 from 
albumin represents the start and end point for RT prediction (Figure 4.3.A). The boxplots 
show the variability of the observed RTs across all DIA files. Peptides 13 and 14 are 
certainly the ones we want to include in the database due to low variability seen in their 





further consideration (Figure 4.3.B). The R-package, MSstats (Choi et al., 2014) was also 
used to obtain a list of intensities for all peptides. Intensities were ranked and peptides with 
zero intensities were excluded. Peptides that were eventually included in the iRT database 
are 15, 13, 5, 14, 22, 3, 19, 18, 9, 4, 6 and 8. These peptides have a high degree of 
correlation (R=0.9889) between the predicted and observed retention time across all DIA 
raw files (Figure 4.4). Having standards is useful for the characterisation and identification of 
peptides (Veenaas, Linusson and Haglund, 2018). The retention time of the last 
chromatographic peak indicated that the chromatographic run was less than 50 minutes 
long. 
 
Figure 4.3. The predicted and observed RT of 23 peptide sequences from the two 
most abundant human proteins. The dot chart shows the wide range of RTs predicted by 
Skyline for the 23 peptides (A). The boxplot shows the variability of the observed RTs by 






Figure 4.4. The residual plot shows the relationship between the SSRCalc and the 
measured RT. The relationship shows a high degree of correlation (R=0.99). 
 
4.4.5. DIA data analysis 
In DDA, individual precursors are selected for fragmentation in a semi-stochastic nature in 
shotgun proteomics favouring the most intense peaks, as a result a low percentage of the 
detectable peptides get fragmented and an even lower number are reliably identified 
(Michalski, Cox and Mann, 2011, Schubert et al., 2015). This is the key aspect to DDA, the 
protein identifiability is much more reproducible than at the peptide level. Since only the 
selected precursors are fragmented, a large proportion of the information is lost. In DIA, in 
contrast, all precursors are fragmented and MS2 data is acquired for all fragment ions. This 
allows to record MS1 and MS2 data from virtually all peptides in a sample without loss of 
information (Gillet et al., 2012, Egertson et al., 2013).  
In this study, the aim is to combine DDA’s strength in discovery proteomics with the 
sensitivity and reproducibility of untargeted DIA (Rauniyar, 2015) to enhance the extraction 
of peptide-specific information from highly multiplexed DIA data in a targeted fashion. DIA 
implementations use wide pre-defined precursor fragmentation windows to acquire 
comprehensive fragment ion data (Ludwig et al., 2018). In this study, all peptides within a 
defined variable mass-to-charge (m/z) window were fragmented (Figure 4.5). This will place 





windows outperforms fixed windows in terms of quantification and identification (Zhang et al., 
2015). For the resulting highly multiplexed ion spectra for all detectable peptides over the 
elution time, an elaborate data processing tool is required (Tujin et al., 2016). Skyline 
software platform (MacLean et al., 2010) was used with settings provided in Table S4.3 of 
the Supporting Material. Skyline is a tool used for many instrument methods for 
interpretation of results. This vendor-neutral, user friendly and active support of Skyline 
made it an attractive option for processing the DIA data in a targeted fashion compared to 
the OpenSWATH software platform (Röst et al., 2014). The quantitative metrics produced for 
529 proteins, 2601 peptides and 3511 precursors. DIA integrations in Skyline were ran twice, 
first the retention time tolerance windows were set to 5-min and then with a 2-min window, 
respectively (Boswell, Abate-Pella and Hewitt, 2015). Fewer peptides were expected for the 
2-min window Skyline document; however, there was no difference in the numbers of 
peptides or the retention times of the peptides between these two Skyline documents using 
these time windows.  
 
Figure 4.5. The isolation window scheme. The measurement windows derived from the 





Using the DDA workflow individual precursors are selected for fragmentation. This approach 
could limit the reliability of peptide identification. DDA data were subjected to traditional 
database searching with the MS-GF+ and MSFragger search engines employed, 
respectively. The protein assembly was then handled with a statistical tool, IDPicker using a 





observed to identify more peptides than the ultrafast MSFragger search. The MSFragger 
search was done with a UniProtKB which provides protein accession with minimal 
redundancy due to human input and the integration with other databases. Therefore, these 
results were used to create a protein list containing the top protein identifiers of interest 
based on RS-score and filtered spectra. In the DIA workflow all precursors are fragmented 
and MS2 data were acquired for all fragment ions. Due to the complexity of the MS2 level 
data, database searching was not used, instead spectral library searching offers the ability to 
extract peptide-centric information from the multiplexed DIA data.  
In this study, we leverage from DDA data to create a target protein and peptide list to 
achieve DIA data analysis in a targeted fashion. The quality and coverage of the spectral 
library is critical for peptide identifications. Two DDA-based spectral libraries was created 
using MS-GF+ and MSFragger search outputs, respectively. Here, we found that the 
MSFragger search outputs created a larger library compared to the MS-GF+ search outputs. 
The MSFragger DDA-based library was used to help create authentic standards derived 
from human albumin and human uromodulin peptides which prove here to be more reliable 
than using retention projection. The availability of open spectral libraries for DIA analysis are 
limited, a comprehensive human spectral library was created by a different laboratory. This 
library was used in the targeted DIA data analysis method using the Skyline software 







Urine Proteome for the Identification of Biomarkers for Paediatric Tuberculosis 
  
This Chapter evaluates the presence of urine protein biomarkers associated with paediatric 
TB. Data-independent acquisition (DIA) mass spectrometry was done by the Steen 
Laboratory as part of The Urine Proteomics Study conducted by Boston Children’s Hospital. 
Unlike the initial analysis in Steen Lab employing Spectronaut software, the protein-level 
quantification and testing for differential abundance were performed on a Skyline document 
using the R-package, MSstats based on a linear mixed-effects model. These comparison 
tests identify the proteins with significantly different means in the data set by estimating fold 
changes and p values that have been adjusted to control the false discovery rate (FDR) at 
0.05.  
 
 5.1. Materials  
  
• RStudio Desktop (https://rstudio.com/products/rstudio/download/#download);  




• A 64-bit computer with Windows 10 operating system, 8 GB of RAM, a quad-core i5 
processor, and more than 50 GB of free disk space. 
 
5.3. Experimental Procedure 
5.3.1. Differential protein abundance testing 
A subset of South African human-immunodeficiency virus (HIV) negative (N=80) samples 
were selected from the integrated Skyline DIA document (see Chapter 4) using dplyr in R. 
The subjects who had active TB (N = 31, Age = 1.5 months – 14 years) were compared with 
controls who had no TB (N=49, Age = 1.5 months – 14 years) (matched for age, sex and 
HIV status) in a randomised blocked study design. The resulting Skyline document was 
converted to MSstats format (Choi et al., 2014) using R. MSstats is suitable for researchers 
with a limited statistics and programming background. Peptides that were associated with 





used to calculate the abundance values for peptides using the median normalisation. The 
quality of the normalisation was visualised using boxplots. To find an additively fit model for 
the data, Tukey median polish was performed. For the comparisons between TB cases and 
controls, MSstats provided model-based estimates of fold changes as well as p values that 
were adjusted to control the FDR at the cut-off 0.05 (Benjamini and Hochberg, 1995). A 
volcano plot was used to visualize the differentially abundant proteins. 
  
5.4. Results and Discussion  
5.4.1. Discovery phase of premature urine protein biomarkers 
 
Epidemiologic studies in industrialized countries and resource-limited countries with high 
burdens of TB found that younger populations, females, and persons of African or Asian 
origins had a higher risk for TB (Rée, 1997; Yang et al., 2004). Even with these statistics, 
paediatric TB has not been prioritised, mainly due to the difficulty in diagnosis. This study 
aims to use an DIA data that has been optimised leveraging the protein and peptide 
identification abilities from DDA data. Generally, two-sample t-tests are used for significance 
testing, in which the relative or absolute abundances for each peptide or protein across the 
condition of interest would be compared. However, in a typically proteomics study samples 
sizes are often too small, which results in uncertainty of the true sample variability. A small 
sample size can exhibit a small observed fold change (Kammers et al., 2015) which is 
biologically meaningless (Mccarthy and Smyth, 2009; Colquhoun, 2014). In a study by 
Clough et al. two MS samples were used to demonstrate that a simultaneous statistical 
model of all the relevant features and conditions yields a higher sensitivity of protein 
quantification as compared to commonly employed alternatives (Clough et al., 2012). Later 
an open-source R-package, MSstats (Choi et al., 2014) was developed to test for differential 
abundance on the protein-level using a linear mixed-effects model. 
 
Overall, 529 proteins were detected with more than 2 peptides in Skyline. For statistical 
analysis, 491 proteins with valid intensity values in all samples were further considered.  In 
this study, a subset of the Skyline document (see Chapter 4) containing fragment ion level 
information (Selevsek et al., 2015) representing a South African HIV negative cohort 
consisting of 31 cases and 49 controls. The MSstats dataProcess function summarizes the 
quantitative experimental information from a set of fragmented peptides as well as the 
intensities, abundances for one condition (case versus control). Peptides that were used in 





replaced with zeros. The q-value reflects the aggregate error required to include an intensity 
value. Many normalisation methods have been adapted from the DNA microarray techniques 
for use on proteomics data (Callister et al., 2006).  MSstats uses median normalisation 
based on the assumption that samples are separated by a constant (Kultima et al., 2009).  
The effects of this step for all proteins are visualised in Figure S5.1 of the Supporting 
Material. Data generated by the MS analysis are prone to biases, which can be accounted 
for with normalisation resulting in more reliable downstream analysis. Due to peptide-to-
peptide variability, MSstats provides a nonparametric test on normalised peptide values, 
thus minimising the number of free parameters, as well as for measuring significance with 
permutation testing (Slama et al., 2018).  
 
For each comparison, a contrast matrix was created. Meena Choi (developer of the MSstats 
R-package) assisted in the development of the contrast matrix. The groupComparison 
function uses the matrix to compute fold changes and p values that were adjusted to control 
the FDR at the cut-off 0.05 (Benjamini and Hochberg, 1995). A volcano plot was used to 
illustrate the significantly expressed proteins (Figure 5.1). The comparisons between the two 
groups, cases and controls were graphically represented to display the quantitative data. 
Three human proteins, leucine-rich alpha-2-glycoprotein (A2GL), aggrecan core protein 
(PGCA) and cartilage intermediate layer protein 2 (CILP2) were identified as statistically 
significant (Figure 5.1). A2GL were upregulated with a 2-fold increase, while PGCA and 
CILP2 were downregulated with FCs between 0 and -1. All proteins detected were quantified 
by group, A2GL was more abundant in TB case samples, while PGCA and CILP2 was more 
abundant in control samples. 
 
A2GL plays a role in transforming growth factor beta receptor binding. This protein is also 
involved in positive regulation of endothelial cell proliferation and the biological response to 
bacterium. In a study by Yang et al. plasma leucine-rich alpha-2-glycoprotein was identified 
as an innovative biomarker for inflammation in association with the progression of End-stage 
renal disease (ESRD) (Yang et al., 2020). PGCA has a binding role for carbohydrates, the 
extracellular matrix structure, hyaluronic acid and metal ions. This protein is also involved in 
cartilage condensation, cell adhesion, the development of the central nervous system, heart 
development and skeletal system development. Aggrecan cleavage is a sign of cartilage 
degeneration in disease such as rheumatoid arthritis and osteoarthritis (Hsueh, Kraus and 
Önnerfjord, 2017; Suna et al., 2018). Limited Gene Ontology (GO) annotations has been 
made for CILP-2; however, it has a related function to PGCA in cartilage. CILP-2 has also 







Figure 5.1. Volcano plot illustrates significantly differentially abundant proteins. The -




Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is widely used 
for such quantitative proteomic investigations. The typical output of such studies is a list of 
identified and quantified peptides from a tool such as Skyline. The biological and clinical 
interest is, however, usually focused on quantitative conclusions at the protein level. MSstats 
was employed to generate comparisons between the two groups, cases and controls for the 
South African TB cohort were graphically represented to display the quantitative data. Three 
human proteins, leucine-rich alpha-2-glycoprotein (A2GL), aggrecan core protein (PGCA) 
and cartilage intermediate layer protein 2 (CILP2) were identified as significantly different. 
A2GL were upregulated with a 2-fold increase and PGCA and CILP-2 were downregulated 
with FCs between 0 and -1. Both PGCA and CILP-2 plays a role in cartilage degeneration, 
while A2GL is an important biomarker for inflammation associated with the progression of 
ESRD. Further investigations should be done to validate these findings. This study 
generated knowledge that could have important clinical applications on urine protein 








Conclusion, limitations, and future recommendations 
 
 
Quality metrics were successfully generated using QuaMeter “IDFree” software on the DDA 
data and SwaMe software on the DIA data. The PCA showed that the batch effects were 
minimal. The distribution of density and the number of scans appeared important to the 
variability for both DIA and DDA, although in DDA they were all related to MS1, whereas in 
DIA they were all related to MS2. TIC impacted only the DDA data but not the DIA, possibly 
because SwaMe comprehensive metrics do not contain any TIC measures. There was also 
no metric for MS1-Density changes in SwaMe; only MS2-Density changes are observed. 
SwaMe does produce a metric for MS1 Count, yet it only appeared a significant source of 
variability in the DDA data. For further studies, the additional metrics generated for SwaMe 
should be included in PCA analysis. A broader diversity of metrics should enable a closer 
look at DIA variability. 
Dissimilarity assessments were performed by calculating Euclidean median distances in the 
major components and comparing run-to-run. Boxplots were used to identify outliers as the 
runs above the top whisker. There were 18 outliers in the DDA experiment and 14 different 
outliers in the DIA experiment, which were excluded during the urine protein biomarker 
discovery phase. Future recommendations would be to exclude the outliers and then redo 
the PCA to identify whether the method detects new possible outliers with the same sources 
of variability. It would also be useful to develop quality control models for dynamic 
performance monitoring that can allow for systematic incorporation of the insights of 
laboratory technicians. The decision-making of whether to re-run those samples is open to 
the researcher, potentially driving experimental costs higher. 
The DDA workflow selected individual precursors for fragmentation. DDA data were 
subjected to traditional database searching via the MS-GF+ and MSFragger search engines. 
Protein assembly was then handled with a statistical tool, IDPicker using a 1% PSM FDR to 
achieve meaningful comparisons. The MS-GF+ search was observed to identify more 
peptides than the ultrafast MSFragger search. The MSFragger search was done with a 
UniProtKB which provides protein accession with minimal redundancy due to human input 
and the integration with other databases. Therefore, these results were used to create a 
protein list containing the top protein identifiers of interest based on reproducibility of 
detection and the number of PSMs observed per protein. In the DIA workflow all precursors 





the MS2 level data, database searching was not used, instead spectral library searching 
offers the ability to extract peptide-centric information from the multiplexed DIA data.  
The DIA data analysis method leveraged DDA data to create lists of quantifiable proteins 
and peptides. This optimisation allows for greater sensitivity in peptide quantification during 
DIA analysis in the Skyline environment. Although MS-GF+ identified more peptides by 
database searching, MSFragger detected more distinct peptides by spectral library creation 
from a smaller set of identified peptides. The magnitude of sensitivity differences between 
the search engines, however, was not large. Future studies may include PSM filtering 
software that employs distributional analysis or machine learning classifiers to boot overall 
sensitivity. 
In this study, commercially available iRT peptides were not spiked into samples during the 
experiment. Standard calibrant peptides were successfully selected from the two most 
abundant proteins commonly found in human urine: serum albumin and uromodulin. This 
allows the Skyline software to predict more accurately when a peptide should appear in a 
50-minute DIA experiment. The output of the DIA analysis method was a list of identified and 
quantified peptides of interest. The biological and clinical interest, however, focusses on the 
quantitative conclusion made at the protein level. MSstats was employed to generate 
comparisons between the two groups, cases and controls for the South African TB cohort 
were graphically represented to display the quantitative data. Three human proteins, leucine-
rich alpha-2-glycoprotein (A2GL), aggrecan core protein (PGCA) and cartilage intermediate 
layer protein 2 (CILP2) were identified as significantly different. A2GL were upregulated with 
a 2-fold increase and PGCA and CILP-2 were downregulated with FCs between 0 and -1. 
Both PGCA and CILP-2 plays a role in cartilage degeneration, while A2GL is an important 
biomarker for inflammation associated with the progression of ESRD. Further investigations 
using new cohorts of patient data or with alternative methods such as ELISA may validate 
these proteins as significantly different. This study generated knowledge that could have 
important clinical applications on urine protein biomarker discovery for paediatric TB.  
We hypothesized that the quantity of specific host proteins in urine is different for children 
with TB compared to symptomatic control children who do not have TB. In this study, we 
showed that by using an optimised DIA data analysis method leveraging DDA data we can 
identify abundantly differentially expressed proteins. Further investigation is required to 
determine the impact of the significant proteins, and whether they would hold up during the 
validation phase. This study highlights the ability of the advances in MS technology to 










Table S3.1. QuaMeter IDfree and SwaMe metrics and execution 
The QuaMeter software was executed with this command line: 
quameter.exe *. mzML -cpus 1 -MetricsType idfree -OutputFilepath metrics.tsv 
 
The SwaMe software was executed with this command line: 
Yamato.Console.exe *. mzML -d 10 –dir true 
 
The quameter.cfg file used for the orbitrap configuration included the following: 
ChromatogramMzLowerOffset = “.05mz” 
ChromatogramMzUpperOffset = “.05mz” 
Instrument = “Orbi” 
 
Table S3.2. The undivided quality metrics generated by SwaMe explained (Kriek, 
unpublished) 
Undivided metrics   
 Metric  Definition 
MissingScans 
The number of scans where there was not a single ion 
detected. 
RTDuration 
Difference between the first scan start time and the last scan 
start time 
SwathSizeDifference Difference between the largest swath and the smallest swath 
MS2Count Number of MS2 scans in the entire run 
MS1Count Number of MS1 scans in the entire run 
SwathsPerCycle Number of swaths in the same cycle 
TotalMS2IonCount Number of ions detected in all MS2scans across the run 
TotalMS1IonCount Number of ions detected in all MS1scans across the run 
MS2Density50 The median number of ions in all MS2 scans 











Table S3.3. Medians and interquartile ranges (IQR) of dissimilarity 
 Samples Median IQR 
Figure 3.3A: DDA 
experiments from 
the Thermo Q-
Exactive MS (in the 
same lab) 
237 4.4 1.8 
Figure 3.3B: DIA 
experiments from 
the Thermo Q-
Exactive MS (in the 
same lab) 








Figure S3.1. Scree plot shows the contribution of variance per component, where 
component 1 and 2 (PC1 and PC2) accounted for the most variance in the DDA dataset (A) 








Table S4.1. Database search engine executions 
Run Philosopher from the command line to download protein sequences from UniProt. 
Execute the following two commands: 
philosopher_windows_amd64.exe workspace --init  
philosopher_windows_amd64.exe database --reviewed --contam --id UP000005640 
 
MSFragger Database Searching command: 
java -d64 -Xmx8G -jar R:\Research\MSFragger-2.3\MSFragger-2.3.jar 20200407-
Tryptic.params raws\*.raw 
 
MS-GF+ Database Searching command: 
java -Xmx8G -jar MSGFPlus.jar -d 20180308-EnsembI-Mtb-Human-Cntms.fasta -t 20ppm 







Table S4.2. 23 peptides for standard calibrant peptide selection. The number label 








Table S4.3. Settings used in the Skyline proteomics environment for optimised DIA analysis. 
Transition settings 
Filter Peptide precursor charges: 2, 3 
  Ion charges: 1 
  Ion types: y, b 
  Product ion selection: From m/z>precursor to 3 ions 
Library Ion match tolerance: 0.5 m/z 
  Pick 3 product ions 
  Select from filtered ion charges and types 
Full-Scan MS/MS filtering 
  DIA Acquisition method 
  Orbitrap product mass analyser 
  Isolation scheme 
  Resolving power 60 000 at 400 m/z 
  Retention time filtering 
  Use only scans within 5 minutes of MS/MS IDs 
Peptide settings 
Prediction Retention time predictor 
  5 min time window 
Library Spectronaut Library 
  Pick peptides matching library 











Figure S5.1. A quality control plot for all endogenous proteins. This plot was generated 
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